HEPA — what changed in the latest 10-Q
A section-by-section comparison of HEPA's newest periodic SEC filing (10-K/10-Q) against the prior same-form filing: paragraphs added and removed per section, with verbatim excerpts. Purely a deterministic text diff — no similarity scores, no directional read, not investment advice.
Comparing 10-Q · 2026-08-13 vs the prior 10-Q · 2026-05-14
| Section | Outcome | Added | Removed | Minor | Unchanged |
|---|---|---|---|---|---|
| MD&A | Text added/removed | +18 | −12 | ~9 | 17 |
| Controls & procedures | Text added/removed | 0 | 0 | ~3 | 10 |
| Risk factors | No material changes reported (points to the 10-K) | — | — | — | — |
| Other information | Text added/removed | 0 | 0 | ~1 | 0 |
Counts are paragraphs; added/removed means text added or removed vs the prior filing — no direction or judgement implied.
Not shown (absent or not faithfully extractable): Market risk (Item 3), Legal proceedings
Representative excerpts
Up to 5 excerpts of about 300 characters per section, quoted verbatim from the two SEC filings.
MD&A
Text added vs the prior filing · source: 10-Q · 2026-08-13
Change in fair value of derivative financial instruments—warrants (42,989) 698,073 (741,062)
We had no revenues during the three months ended June 30, 2026 and 2025, because we have not commercialized any of our medical diagnostic products and we do not expect to have such products for several years, if at all.
Research and development expenses for the three months ended June 30, 2026 and 2025 was approximately $0.1 million and $0.4 million, respectively. The decrease in research and development expense in 2026 is primarily related to purchased in-process research and development from the New Day asset acq…
General and administrative expenses for the three months ended June 30, 2026 and 2025 was approximately $1.2 million and $0.9 million, respectively. The increase of $0.2 million was primarily due to a $0.3 million increase in personnel costs of our general and administrative employees, $0.1 million …
Asset impairment loss for the three months ended June 30, 2026 and 2025 was $0 and $0.4 million, respectively. The decrease in asset impairment loss is related to the asset from the New Day license agreement that was fully impaired in prior year.
Text removed vs the prior filing · source: 10-Q · 2026-05-14
We had no revenues during the three months ended March 31, 2026 and 2025, respectively, because we have not commercialized any of our medical diagnostic products and we do not expect to have such products for several years, if at all.
Research and development expenses for the three months ended March 31, 2026 and 2025 was $70,000 and $22,235, respectively. The $70,000 incurred in 2026 is primarily related to Cirna licensing agreement, whereas the $22,235 incurred in prior period was primarily due to certain residual costs to clos…
General and administrative expenses for the three months ended March 31, 2026 and 2025 was $0.7 million and $1.3 million, respectively. The decrease of $0.5 million was primarily due to a $0.4 million decrease in legal fees and accounting fees, $0.1 million decrease in insurance, and $0.2 million de…
We have funded our operations through March 31, 2026 primarily through the issuance of convertible preferred stock, warrants, the issuance and sale of shares of our common stock, and subsequent issuances of shares of our common stock through at-the market offerings.
On April 21, 2026, we entered into securities purchase agreements (the “Agreements”) with certain accredited investors (the “Investors”) pursuant to which the Company agreed to sell and issue to the Investors in a private placement offering (the “Offering”), an aggregate offering of 17,500,000 share…
How to read Risk Factors (Item 1A) in a 10-Q
A 10-Q risk-factor section usually takes one of three forms; this page classifies it as one of:
- Pointer — the filer states there have been no material changes and points back to the annual 10-K risk factors; there is no own risk text to compare this quarter.
- Partial update — the filer carves out specific updated risks ("except as set forth below"); the excerpts show exactly what is new this quarter.
- Restated in full — the quarter carries the complete risk-factor text. When the prior quarter was only a pointer there is no prior full text to diff against, so the page flags the section as restated instead.
This describes the filing structure only — it is never a judgement on whether risk went up or down.
Source: text-level diff of the two SEC EDGAR filings · deterministic (no AI-generated content) · for reference only · not investment advice